Non-Coding RNAs in Breast Cancer: Intracellular and Intercellular Communication
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Non-coding RNAs (ncRNAs) are regulators of intracellular and intercellular signaling in breast cancer. ncRNAs modulate intracellular signaling to control diverse cellular processes, including levels and activity of estrogen receptor α (ERα), proliferation, invasion, migration, apoptosis, and stemness. In addition, ncRNAs can be packaged into exosomes to provide intercellular communication by the transmission of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) to cells locally or systemically. This review provides an overview of the biogenesis and roles of ncRNAs: small nucleolar RNA (snRNA), circular RNAs (circRNAs), PIWI-interacting RNAs (piRNAs), miRNAs, and lncRNAs in breast cancer. Since more is known about the miRNAs and lncRNAs that are expressed in breast tumors, their established targets as oncogenic drivers and tumor suppressors will be reviewed. The focus is on miRNAs and lncRNAs identified in breast tumors, since a number of ncRNAs identified in breast cancer cells are not dysregulated in breast tumors. The identity and putative function of selected lncRNAs increased: nuclear paraspeckle assembly transcript 1 (NEAT1), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), steroid receptor RNA activator 1 (SRA1), colon cancer associated transcript 2 (CCAT2), colorectal neoplasia differentially expressed (CRNDE), myocardial infarction associated transcript (MIAT), and long intergenic non-protein coding RNA, Regulator of Reprogramming (LINC-ROR); and decreased levels of maternally-expressed 3 (MEG3) in breast tumors have been observed as well. miRNAs and lncRNAs are considered targets of therapeutic intervention in breast cancer, but further work is needed to bring the promise of regulating their activities to clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186
miRBase: annotating high confidence microRNAs using deep sequencing data
Kozomara, A., & Griffiths-Jones, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1181 · Cited by 5,073
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053 · cited 3×
“miR-125a-5p CDKN1, NTRK3, TP53, VEGFA, ERBB2, ERBB3, BAK1, KLF13, ARID3B, ELAV1 lncRNAs that act as ceRNAs for miR-125a-5p include HOTAIR, ANRIL, and HOXA11-AS (reviewed in [28]) NFκB pathway [232] Lower in breast tumors [233].”
BackgroundInfluentialPalbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
An atlas of active enhancers across human cell types and tissues
The FANTOM Consortium, Andersson, R., Gebhard, C., Miguel-Escalada, I., Hoof, I., Bornholdt, J., Boyd, M., Chen, Y., Zhao, X., Schmidl, C., et al. (2014) · Nature · doi:10.1038/nature12787 · Cited by 2,550 · cited 1×
“LncRNAs are defined as ncRNAs of >200 nucleotides [64].”
BackgroundThe Noncoding RNA Revolution—Trashing Old Rules to Forge New Ones
Cech, T. R., & Steitz, J. A. (2014) · Cell · doi:10.1016/j.cell.2014.03.008 · Cited by 2,524
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218
Extensive translation of circular RNAs driven by N6-methyladenosine
Yang, Y., Fan, X., Mao, M., Song, X., Wu, P., Zhang, Y., Jin, Y., Yang, Y., Chen, L.-L., Wang, Y., et al. (2017) · Cell Research · doi:10.1038/cr.2017.31 · Cited by 1,855 · cited 1×
“Circular RNAs (circRNAs) Circular RNAs: Four types: circular RNAs from introns, exonic circRNAs, exon-intron circRNAs (EIciRNA), and intergenic circRNAs [29] • Size range from a few hundred to >1000 nt • Nucleus < cytoplasm • Nuclear export is active and size-dependent, involving DDX39B and DDX39A [30] • Generally for…”
BackgroundCircular RNA: a new star of noncoding RNAs
Qu, S., Yang, X., Li, X., Wang, J., Gao, Y., Shang, R., Sun, W., Dou, K., & Li, H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.003 · Cited by 1,808 · cited 1×
“circRNAs can act as competing endogenous RNA (ceRNA, also called ‘sponge’) for microRNAs, thus reducing miRNA repression of their target mRNAs [75].”
BackgroundMicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y.-Y. (2008) · Cell Research · doi:10.1038/cr.2008.24 · Cited by 1,051
Exosomes and Ectosomes in Intercellular Communication
Meldolesi, J. (2018) · Current Biology · doi:10.1016/j.cub.2018.01.059 · Cited by 944
Fasanaro, P., D'Alessandra, Y., Di Stefano, V., Melchionna, R., Romani, S., Pompilio, G., Capogrossi, M. C., & Martelli, F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800731200 · Cited by 912 · cited 1×
“miR-210-3p ISCU and COX10 [199]; FGFRL1, RAD52; BDNF, PTPN1, ISCU, NCAM1, and the lncRNA XIST [200] Cell proliferation, migration, and invasion High miR-210 was associated with lower relapse-free survival [201].”
BackgroundCircular RNAs: analysis, expression and potential functions
Barrett, S. P., & Salzman, J. (2016) · Development · doi:10.1242/dev.128074 · Cited by 859
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene
Lu, Z., Liu, M., Stribinskis, V, Klinge, C. M., Ramos, K. S., Colburn, N. H., & Li, Y. (2008) · Oncogene · doi:10.1038/onc.2008.72 · Cited by 711 · cited 1×
“miR-21-5p PTEN, PDCD4 [106,139]; NFIB [122]; RASA1 and RASA2 [140]; BTG2, FBXO11, MARCKS, RECK, and TPM1 [141]; TIMP3 [115] miR-21 negatively regulates lncRNAs GAS5 and CASC2 [28] PI3K-AKT signaling, apoptosis Consistently increased in breast tumors and in plasma from BCa patients [56].”
BackgroundSelf-citationMechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651 · cited 1×
“Unfortunately, 30–40% of patients develop resistance to endocrine therapies and develop metastatic disease [3,4].”
BackgroundEpitranscriptome sequencing technologies: decoding RNA modifications
Li, X., Xiong, X., & Yi, C. (2017) · Nature Methods · doi:10.1038/nmeth.4110 · Cited by 447
Chen, Z., Li, Y., Zhang, H., Huang, P., & Luthra, R. (2010) · Oncogene · doi:10.1038/onc.2010.193 · Cited by 426
microRNA target prediction programs predict many false positives
Pinzón, N., Li, B., Martinez, L., Sergeeva, A., Presumey, J., Apparailly, F., & Seitz, H. (2017) · Genome Research · doi:10.1101/gr.205146.116 · Cited by 273 · cited 1×
“Examples include miRTarBase, PicTar, miRanda, and MirAncesTar, although these programs predict false positives and false negatives (reviewed in [85]).”
BackgroundJorjani, H., Kehr, S., Jedlinski, D. J., Gumienny, R., Hertel, J., Stadler, P. F., Zavolan, M., & Gruber, A. R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw386 · Cited by 257 · cited 1×
“Some snoRNAs are expressed in a cell-specific manner, including SNORD46 and SNORD42A in mammary glands and lymphoblastoid cells in the ENCODE (Encyclopedia of DNA elements) dataset (reviewed in [69]).”
BackgroundLessons from miR-143/145: the importance of cell-type localization of miRNAs
Kent, O. A., McCall, M. N., Cornish, T. C., & Halushka, M. K. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku461 · Cited by 200 · cited 1×
“miR-145 RASA1, MEKK, EGFR [245]; TGFNR2 and SMAD3 [246] lncRNAs act as ceRNAs for miR-145-5p: TUG1 and MALAT1 [246,247]; CRNDE in gastric cancer cells [248], LINC-ROR in gastric cancer cells [249], and PCAT1 in prostate cancer cells [250] RAS signaling in basal-like BCa [244].”
BackgroundMicroRNA-99 Family Targets AKT/mTOR Signaling Pathway in Dermal Wound Healing
Jin, Y., Tymen, S. D., Chen, D., Fang, Z. J., Zhao, Y., Dragas, D., Dai, Y., Marucha, P. T., & Zhou, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064434 · Cited by 172 · cited 1×
“miR-99a-5p IGF1R, AKT1 [226]; HOXA1 [227]; RAVER2, FGFR2, IGF1R, MTOR, AGO2 TGFβ pathway [228]; mTOR signaling pathway [229] Downregulated in BCa tissues [56]; downregulated in DCIS [230]; low serum miR-99a is a poor prognostic indicator in BCa correlating with lymph node metastasis, and distant metastasis [231].”
BackgroundResolving subcellular miRNA trafficking and turnover at single-molecule resolution
Pitchiaya, S., Heinicke, L. A., Park, J. I., Cameron, E. L., & Walter, N. G. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.075 · Cited by 98 · cited 1×
“The non-incorporated passenger strand of miRNA is degraded [98].”
BackgroundArm Selection Preference of MicroRNA-193a Varies in Breast Cancer
Tsai, K.-W., Leung, C.-M., Lo, Y.-H., Chen, T.-W., Chan, W.-C., Yu, S.-Y., Tu, Y.-T., Lam, H.-C., Li, S.-C., Ger, L.-P., et al. (2016) · Scientific Reports · doi:10.1038/srep28176 · Cited by 84 · cited 1×
“miR-193a-3p DDAH1 [195]; WT1 [196] Cell growth [196] miR-193a-5p was decreased, but no significant differences in miR-193a-3p in BCa [197].”
Background
Cited by
Liquid biopsy in cancer: current status, challenges and future prospects
Ma, L., Guo, H., Zhao, Y., Liu, Z., Wang, C., Bu, J., Sun, T., & Wei, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02021-w · Cited by 712
Aging, melatonin, and the pro- and anti-inflammatory networks
Hardeland, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051223 · Cited by 337
Estrogenic control of mitochondrial function
Klinge, C. M. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101435 · Cited by 293
Self-citation
Metadata
- Authors
- Klinge, C. M.
- Venue
- Non-Coding RNA
- Publisher
- MDPI AG
- Published
- 2018-12-12
- Volume
- 4
- Issue
- 4
- Pages
- 40
- ISSN
- 2311-553X (ISSN-L)
- OpenAlex
- W2904623992
- Cited by
- 163
- References
- 24
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.